the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Tepotinib Phase II in NSCLC Harbouring MET Exon 14 (METex14) Skipping Alterations
Official Title A Phase II, Single-arm Trial to Investigate Tepotinib in Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations (VISION)
Principal Investigator Patel, Jyoti
Brief Summary This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Gender All
Ages 18 Years
Enrollment 120
Accepts Healthy Volunteers No
Lead Sponsor EMD Serono Research & Development Institute, Inc.Industry
Collaborator Merck KGaAIndustry
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name Ravi Salgia
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI